Advertisement

Photodynamic Therapy: A Novel Approach to the Treatment of AMD

  • I. Barbazetto
  • Ursula Schmidt-Erfurth

Abstract

Age-related macular degeneration (AMD) is a degenerative eye disease that can cause severe and irreversible loss of central vision. While most patients with AMD experience only a slow, moderate decrease of visual acuity as a result of atrophic changes of the retina, 10% of patients suffer from a severe and rapidly developing visual loss. According to literature and clinical experience, up to 90% of this significantly affected group present with the neovascular form of AMD (Bressler et aI.1982; Guyer et al.1986; Bressler et al.1988). This form is characterized by the development of abnormal blood vessels under the retina, which leak fluid, lipids and blood.Over time the leakage leads to fibrosis of the central retina with loss of photoreceptors and concomitant vision decline (Bressler et al.1982). In North America and Europe this is the leading cause of legal blindness in people over 65 years of age (Leibowitz et al.1980).

Keywords

Visual Acuity Retinal Pigment Epithelium Photodynamic Therapy Choroidal Neovascularization Pathologic Myopia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aveline B, Hasan T, Redmond RW (1994) Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A ( BPD-MA ). Photochem Photobiol 59: 328–335PubMedCrossRefGoogle Scholar
  2. Aveline BM, Hasan T, Redmond RW (1995) The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). 1 Photochem Photobiol B 30: 161–169CrossRefGoogle Scholar
  3. Berking GJ, Hoyng CB, Van der Maazen et al. (1998) A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefe’s Arch Clin Exp Ophthalmol 236: 321–325CrossRefGoogle Scholar
  4. Blumenkranz MS,Woodburn KW, Qing F et al. (2000) Lutetium texaphyrin (Lu-Tex):a potential new agent for ocular fun-dus angiography and photodynamic therapy. Am J Ophthalmol 129: 353–362PubMedCrossRefGoogle Scholar
  5. Boyle RW, Dolphin D (1996) Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 64: 469–485PubMedCrossRefGoogle Scholar
  6. Bressler NM (1986) Submacular surgery:are randomized trials necessary? Arch Ophthalmol 113: 1557–1560CrossRefGoogle Scholar
  7. Bressler NM et al. (1982) Natural course of choroidal neovascular membranes within the fovea) avascular zone in senile macular degeneration.Am J Ophthalmol 93: 157–163Google Scholar
  8. Bressler NM, Bressler SB, Fine SL (1988) Age-related macular degeneration. Sury Ophthalmol 32: 375–413CrossRefGoogle Scholar
  9. Bressler SB, Bressler NM, Fine SL et al. (1982) Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93: 157–163PubMedGoogle Scholar
  10. Brown SG (1998) Science, medicine and the future. New techniques in laser therapy. BMJ 316: 754–757CrossRefGoogle Scholar
  11. Diamond I et al. (1972) Photodynamic therapy of malignant tumors. Lancet 2: 1175PubMedCrossRefGoogle Scholar
  12. Dougherty TJ et al. (1975) Photoradiation therapy II. Cure of animal tumors with hematoporphyrine and light. J Natl Cancer Inst 55: 115–121PubMedGoogle Scholar
  13. Dougherty TJ et al. (1978) Photoradiation therapy for the treatment of malignant tumors. Cancer Res 38: 26282635Google Scholar
  14. DoughertyTJ et al. (1979) Photoradiation in the treatment of recurrent breast carcinoma. J Natl Cancer Inst 62: 231237Google Scholar
  15. Dougherty TJ et al. (1992) Historical perspective. In: Enderson BW and Dougherty TJ (eds) Photodynamic therapy: basic principles and clinical applications. Marcel Dekker, New York, pp 1–18Google Scholar
  16. Dougherty TJ, Gomer CJ, Henderson BW et al. (1998) Photodynamic therapy.J Natl Cancer Inst 90: 889–905CrossRefGoogle Scholar
  17. Eckardt C, Eckardt U, Conrad HG (1999) Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol 237: 313–325PubMedCrossRefGoogle Scholar
  18. Favilla I, Favilla ML, Gosbell AD et al. (1995) Photodynamic therapy: a five-year study of its effectiveness in the treatment of posterior uveal melanoma and evaluation of hematoporphyrin uptake and phototoxicity of melanoma cells in tissue culture. Melanoma Res 5: 355–364PubMedCrossRefGoogle Scholar
  19. Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14: 323–328PubMedGoogle Scholar
  20. Fingar VH, Wilman Ti, Wiehle SA (1992) The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability and leukocyte adhesion. Cancer Res 52: 4914–4921PubMedGoogle Scholar
  21. Flower RW, Snyder WJ (1999) Expanded hypothesis on the mechanism of photodynamic therapy action on choroidal neovascularization. Retina 19: 365–369PubMedCrossRefGoogle Scholar
  22. GohtoY,Obana A, Kanai M,Nagata S,MikiT,Nakajima S (2000) Photodynamic therapy for corneal neovascularization using topically administered ATX-S10 ( Na ). Ophthalmic Surg Lasers 31: 55–60Google Scholar
  23. GohtoY,Obana A, Kanai M, Nagata S, Nakajima S, Miki T (2001) Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATXS10(Na). Exp Eye Res 72: 13–22CrossRefGoogle Scholar
  24. Gomer O (1989) Photodynamic therapy in the treatment of malignancies. Sem Hematol 26: 27–34Google Scholar
  25. Gomer CJ (1991) Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 54: 1093–1097PubMedCrossRefGoogle Scholar
  26. Gomer CJ et al. (1983) Hematoporphyrine-derivate photoradiation therapy for the treatment of intraocular tumors:examination of acute normal ocular tissue toxicity. Cancer Res 43: 721–727PubMedGoogle Scholar
  27. Gomer CJ et al. (1984) Hematoporphyrine-derivate photoradiation-induced damage to normal and tumor tissue of the pigmented rabbit eye. Curr Eye Res 3: 229–237PubMedCrossRefGoogle Scholar
  28. Guyer DR et al. (1986) Subfoveal choroidal neovascular membranes in age-related macular degeneration.Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 104: 702–705PubMedCrossRefGoogle Scholar
  29. Hamovici R, Kramer M, Miller JW et al. (1997) Localization of lipoprotein-delivered benzoporphyrin derivate in the rabbit eye. Curr Eye Res 16: 83–90CrossRefGoogle Scholar
  30. Hasan T, Parrish JA (1997) Photodynamic therapy of cancer. In Holland 1F (ed) Cancer medicine. Williams & Wilkins, Baltimore, pp 739–751Google Scholar
  31. He J, Larkin HE, Li YS, et al. (1997) The synthesis, photophysical and photobiological properties and in vitro structure-activity relationships of a set of silicone phthalocyanine PDT photosensitizers. Photochem Photobiol 65: 581–586PubMedCrossRefGoogle Scholar
  32. Henderson BW, DoughertyTJ (1992) How does photodynam- ic therapy work? Photochem Photobiol 55: 145–157PubMedCrossRefGoogle Scholar
  33. Hilf R, Smail DB, Murant RS et al. (1984) The synthesis, photo-physical and photobiological properties and in vitro structure-activity relationships of a set of silicon phthalocyanine PDT photosensitizers. Photochem Photobiol 65: 581–586Google Scholar
  34. Holz FG et al. for the RAD Study Group (1999) Results of a prospective, randomized, controlled, double blind multicenter trial on external beam radiation therapy for subfoveal choroidal neovascularization secondary to ARMD (RAD Study). Invest Ophthalmol Vis Sci 40 (suppl):2115Google Scholar
  35. Joni G (1990) Factors controlling the selectivity and efficiency of tumor damage in photodynamic therapy. Lasers Med Sci 5: 115–120CrossRefGoogle Scholar
  36. Kliman GH, Puliafito CA, Stern D et al. (1994) Phthalocyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Laser Surg Med 15: 2–10CrossRefGoogle Scholar
  37. Leibowitz H et al. (1980) The Framingham Eye Study Monograph:an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1977. Sury Ophthalmol 24: 355Google Scholar
  38. Levy JG (1994) Photosensitizers in photodynamic therapy. Semin Oncol 21 (suppl 15): 4–10PubMedGoogle Scholar
  39. Levy JG (1995) Photodynamic therapy. Trends Biotechnol 13: 14–18PubMedCrossRefGoogle Scholar
  40. Lipson RL, Baldes El, Olsen EM (1961) Hematoporphyrin derivate: a new aid for endoscopic detection of malignant disease.J Thoracic Caridovascular Surg 42: 623–629Google Scholar
  41. Machemer R, Steinhorst UH (1993) Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefe’s Arch Clin Exp Ophthalmol Nov; 231 (11): 635–641CrossRefGoogle Scholar
  42. Macular Photocoagulation Study Group (1986) Recurrent choroidal neovascularization after argon laser treatment for neovascular maculopathy.Arch Ophthalmol 104:503512Google Scholar
  43. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy: five-year results from two randomized clinical trials. Arch Ophthalmol 109: 1109–1114CrossRefGoogle Scholar
  44. Macular Photocoagulation Study Group (1994) Visual outcomes after laser photocoagulation for subfoveal choroidal neovascularization secondary to age related macular degeneration:the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112: 480–484CrossRefGoogle Scholar
  45. Mainster MA, Reichel E (2000) Transpupillary thermotherapy for age-related macular degeneration:long-pulse photo-coagulation, apoptosis and heat shock proteins. Ophthalmic Surg Lasers 31: 359–373PubMedGoogle Scholar
  46. Meyer-Betz F (1913) Untersuchungen ueber die biologische (photodynamische) Wirkung des Hematoporphyrins and anderer Derivate des Blut-and Gallenfarbstoffes. Dtsch Klin Med 112: 476–503Google Scholar
  47. Miller H, Miller BB (1993) Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 111: 855–860PubMedCrossRefGoogle Scholar
  48. Miller JW, Schmidt-Erfurth U,Sickenberg M et al. (1999) Photo-dynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration:results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117: 1161–1173PubMedCrossRefGoogle Scholar
  49. Miller JW, Walsh AW, Kramer M et al. (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113: 810–818PubMedCrossRefGoogle Scholar
  50. Mori K, Yoneya S, Ohta M, Sano A, Anzai K, Peyman GA, Moshfeghi DM (1999) Angiographic and histological effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology 106: 1384–1391PubMedCrossRefGoogle Scholar
  51. Moshfeghi DM, Peyman GA, Moshfeghi AA, Khoobehi B, Primbs GB, Crean DH (1998) Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers 29: 663–668PubMedGoogle Scholar
  52. Moshfegi DM, Peyman GA, Khoobehi B, Crean DH (1995) Photodynamic occlusion of retinal vessels using tin ethyl etiopurpurin (SnET2), an efficacy study. Invest Ophthalmol Vis Sci 36: S115Google Scholar
  53. Murphre AL, Cote M, Gomer C1(1987) The evolution of photo-dynamic therapy techniques in the treatment of intraocular tumors. Photochem Photobiol 46: 913–919Google Scholar
  54. Nishiwaki H, Danna S, Grebe R et al. (1998) Laser targeted photodynamic therapy occludes experimental choroidal neovascularization without visible damage to RPE and choriocapillaris. Invest Ophthalmol Vis Sci 39: 5276Google Scholar
  55. Obana A, Gohto Y, Kanai M,Nakajima S, Kaneda K, Miki T (2000) Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. Arch Ophthalmol 118: 650–658Google Scholar
  56. Ochsner M (1997) Photophysical and photobiological processes in the photodynamic therapy of tumors. 1 Photochem Photobiol B 39: 1–18Google Scholar
  57. Onishi Y,Yamana Y, Minei M (1986) Photoradiation therapy using argon laser and a hematoporphyrin derivate for retinoblastoma–preliminary report. Jpn J Ophthalmol 30: 409–419Google Scholar
  58. Peyman GA,Kazi AA, Moshfeghi D,Unal M,Khoobehi B,Yoneya S, Mori K, Rivera I (2000) Threshold and retreatment parameters of NPe6 photodynamic therapy in retinal and choroidal vessels. Ophthalmic Surg Lasers JulAug; 31: 323–327Google Scholar
  59. Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alpha-2a is ineffective for patients with choroidal neovascularization secondary to age related macular degeneration: results of prospective, randomized, placebo-controlled clinical trial. Arch Ophthalmol 115: 865–882CrossRefGoogle Scholar
  60. QLT/ Novartis press release (February 7th, 2001) Favorable Visudyne clinical results announced for occult and pathologic myopia patients.Google Scholar
  61. Raab O (1900) Ueber die Wirkung fluorescierender Stoffe auf Infusorien. Z Biol 39: 524–546Google Scholar
  62. Reichel E, Berrocal AM, Ip M et al. (1999) Transpupillary thermotherapy of occult subfoveal neovascularization in patients with age related macular degeneration. Ophthalmology 106: 1908–1914PubMedCrossRefGoogle Scholar
  63. Richter AM et al. (1994) Non-oncologic potentials for the photodynamic therapy. Proc Soc Photo-Optical Instr Eng 20778: 293–304Google Scholar
  64. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D, Levy JG (1990) Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 15: 231–244CrossRefGoogle Scholar
  65. Richter AM, Kelly B, Chow J et al. (1987) Preliminary studies on a more effective phototoxic agent than hematoporphyrin.J Natl Cancer Inst 79: 1327–1332PubMedGoogle Scholar
  66. Richter AM,Waterfield E, Jain AK et al. (1993) Liposomal delivery of a photosensitizer, benzoporphyrin monoacid ring A ( BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 57: 1000–1006PubMedCrossRefGoogle Scholar
  67. Roberts WG, Hasan T (1992) Role of neovasculature and vascular permeability on the tumor retention of photodynamic therapy. Cancer Res 52: 924–930PubMedGoogle Scholar
  68. Rowe PM (1998) Photodynamic therapy begins to shine (news). Lancet 351: 1496PubMedCrossRefGoogle Scholar
  69. Schmidt-Erfurth U (1999) Indocyanine green angiography and retinal sensitivity after photodynamic therapy of subfoveal choroidal neovascularization. Sem Ophthalmol 14: 35–44CrossRefGoogle Scholar
  70. Schmidt-Erfurth U, Bauman W, Gragoudas E, Flotte TJ, Michaud NA, Birngruber R, Hasan T (1994a) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101: 89–99PubMedGoogle Scholar
  71. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T (1997) Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer 75 (1): 54–61PubMedCrossRefGoogle Scholar
  72. Schmidt-Erfurth U, Hasan T (2000) Mechanism of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Sury Ophthalmol 45: 195–214CrossRefGoogle Scholar
  73. Schmidt-Erfurth U, Hasan T, Gragoudas E et al. (1994b) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101: 1953–1961PubMedGoogle Scholar
  74. Schmidt-Erfurth U, Laqua H (2001) Photodynamische Therapie: Empfehlungen fuer Indikation und Behandlung. Ophthalmologe 98: 216–219Google Scholar
  75. Schmidt-Erfurth U,MillerJW,Sickenberg M et al. (1999) Photo-dynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration:results of retreatments in a phase 1 and 2 study.Arch Ophthalmol 117: 1177–1187PubMedCrossRefGoogle Scholar
  76. Schmidt-Erfurth U, Miller JW, Sickenberg M, Bunse A, Laqua H et al. (1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefe’s Arch Clin Exp Ophthalmol 236: 365374Google Scholar
  77. Schuitmaker JJ, van Best JA, van Delft JL et al. (1990) Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results. Invest Ophthalmol Vis Sci 31: 14441450Google Scholar
  78. Soubrane G, Bressler NM (2001) Treatment of subfoveal choroidal neovascularization in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 85: 483–495PubMedCrossRefGoogle Scholar
  79. Spaide RF, Guyer RD, McCormick B et al. (1998) External beam radiation therapy for choroidal neovascularization.Ophthalmol 105: 24–30Google Scholar
  80. Specht KG, Rodgers MA (1990) Depolarization of mouse myeloma cell membranes during photodynamic action. Photochem Photobiol 51: 319–324PubMedCrossRefGoogle Scholar
  81. Tao J, Sanghera JS, Pelech SI et al. (1996) Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrine derivates. J Biol Chem 271: 2710727115Google Scholar
  82. Thomas EL, Langhofer M (1987) Closure of experimental sub-retinal neovascular vessels with dihematoporphyrin ether augmented argon green laser photocoagulation. Photochem Photobiol46: 881–886Google Scholar
  83. Thomas EL, Rosen R, Murphey E et al. (1998) Purlytin (SnET2)photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans. Invest Ophthalmol Vis Sci 39:S. 242Google Scholar
  84. Treatment of Age-related Macular Degeneration with Photo-dynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials TAP report 1. Arch Ophthalmol 117: 1329–1345Google Scholar
  85. Treatment of Age-related Macular Degeneration with Photo-dynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials–TAP report 2. Arch Ophthalmol 119: 198–207Google Scholar
  86. Tse DT, Dutton JJ, Weingeist TA et al. (1984) Hematoporphyrin photoirradiation therapy for intraocular and orbital malignant melanoma. Arch Ophthalmol 102:833–838 VIP Report, in printGoogle Scholar
  87. Von Tappeiner H, Jodlbauer A (1904) Ueber die Wirkung der photodynamischen (fluoresceirenden) Stoffe auf Protozoan and Enzyme. Dtsch Arch Klin Med 80: 427–428Google Scholar
  88. Young SW, Woodburn KW, Wright M et al. (1996) Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol 63: 892–897PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • I. Barbazetto
  • Ursula Schmidt-Erfurth

There are no affiliations available

Personalised recommendations